Éric Vigneault1,2, Josée Savard1,3,4, Marie-Hélène Savard1,3, Hans Ivers1,3,4, Philippe Després1,2,3,5, William Foster2, André-Guy Martin1,2, Vincent Fradet1,3,6. 1. CHU de Québec-Université Laval Research Centre; Quebec City, QC, Canada. 2. Department of Radiation Oncology, CHU de Québec-Université Laval; Quebec City, QC, Canada. 3. Université Laval Cancer Research Centre; Quebec City, QC, Canada. 4. School of Psychology, Université Laval; Quebec City, QC, Canada. 5. Département de Physique, de Génie Physique et d'Optique, Université Laval; Quebec City, QC, Canada. 6. Department of Surgery, Université Laval; Quebec City, QC, Canada.
Abstract
INTRODUCTION: This study aims to empirically validate the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC), a measure of health-related quality of life for prostate cancer patients. METHODS: Two hundred fifty-one participants completed a battery of self-report scales, including the French-Canadian version of the EPIC, after having received radiation therapy or radical prostatectomy for prostate cancer. RESULTS: The internal consistency for the urinary incontinence, bowel, and sexual domains of the EPIC-26 was high (Cronbach's alpha coefficients from 0.80-0.92), while coefficients for the urinary irritation/obstruction (0.59) and hormonal (0.67) domains were lower. Item-total correlations (rs=0.15-0.85), and temporal stability (rs=0.72-0.93) generally supported the reliability of the instrument. The five-factor structure of the EPIC-26 was confirmed for the most part. The construct validity of the instrument was also supported by high correlations obtained between each domain and measures assessing similar constructs (rs=-0.56-0.83). The EPIC also showed an excellent sensitivity to change with significant differences obtained on EPIC scores (all p<0.05) between pre- and post-prostate cancer treatment. CONCLUSIONS: The psychometric qualities of the French-Canadian version of the EPIC are well-supported, thus providing a valid tool to assess health-related quality of life in prostate cancer patients.
INTRODUCTION: This study aims to empirically validate the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC), a measure of health-related quality of life for prostate cancerpatients. METHODS: Two hundred fifty-one participants completed a battery of self-report scales, including the French-Canadian version of the EPIC, after having received radiation therapy or radical prostatectomy for prostate cancer. RESULTS: The internal consistency for the urinary incontinence, bowel, and sexual domains of the EPIC-26 was high (Cronbach's alpha coefficients from 0.80-0.92), while coefficients for the urinary irritation/obstruction (0.59) and hormonal (0.67) domains were lower. Item-total correlations (rs=0.15-0.85), and temporal stability (rs=0.72-0.93) generally supported the reliability of the instrument. The five-factor structure of the EPIC-26 was confirmed for the most part. The construct validity of the instrument was also supported by high correlations obtained between each domain and measures assessing similar constructs (rs=-0.56-0.83). The EPIC also showed an excellent sensitivity to change with significant differences obtained on EPIC scores (all p<0.05) between pre- and post-prostate cancer treatment. CONCLUSIONS: The psychometric qualities of the French-Canadian version of the EPIC are well-supported, thus providing a valid tool to assess health-related quality of life in prostate cancerpatients.
Authors: Montse Ferrer; Olatz Garin; Joan Pera; Josep Maria Prats; Joan Mendivil; Jordi Alonso; Belén De Paula; Ismael Herruzo; Asunción Hervas; Víctor Macias; Alfonso Mariño; María José Ortiz; Sergio Pastor; Javier Ponce De León; Gemma Sancho Journal: Med Clin (Barc) Date: 2009-02-04 Impact factor: 1.725
Authors: Ted A Skolarus; Rodney L Dunn; Martin G Sanda; Peter Chang; Thomas K Greenfield; Mark S Litwin; John T Wei Journal: Urology Date: 2015-01 Impact factor: 2.649
Authors: J L Donovan; F C Hamdy; J A Lane; D E Neal; M Mason; C Metcalfe; E Walsh; J M Blazeby; T J Peters; P Holding; S Bonnington; T Lennon; L Bradshaw; D Cooper; P Herbert; J Howson; A Jones; N Lyons; E Salter; P Thompson; S Tidball; J Blaikie; C Gray; P Bollina; J Catto; A Doble; A Doherty; D Gillatt; R Kockelbergh; H Kynaston; A Paul; P Powell; S Prescott; D J Rosario; E Rowe; M Davis; E L Turner; R M Martin Journal: N Engl J Med Date: 2016-09-14 Impact factor: 91.245
Authors: Sophie D Fosså; Anne Holck Storås; Eivind A Steinsvik; Tor Aa Myklebust; Lars M Eri; Jon H Loge; Alv A Dahl Journal: Scand J Urol Date: 2016-04-06 Impact factor: 1.612
Authors: Stefanie Schmidt; Olatz Garin; Yolanda Pardo; José M Valderas; Jordi Alonso; Pablo Rebollo; Luis Rajmil; Carlos Garcia-Forero; Montse Ferrer Journal: Qual Life Res Date: 2014-04-19 Impact factor: 4.147
Authors: Mohannad A Awad; Luke Hallgarth; Ghassan A Barayan; Mohammed Shahait; Ramiz Abu-Hijlih; Ala'a Farkouh; Raed A Azhar; Musab M Alghamdi; Ahmad Bugis; Said Yaiesh; Saad Aldousari; Alaeddin Barham; Mohamed Saed; Ayman Moussa; Waleed Hassen; Shelly Naud; Mark K Plante; Richard Grunert Journal: Arab J Urol Date: 2021-11-28